Remimazolam infusion associated with easier mask ventilation than propofol during anaesthesia induction
A randomised controlled trial compared anaesthesia induction with continuous remimazolam infusion (12 mg/kg/h) versus target-controlled propofol infusion (4 μg/mL) in 76 adult patients scheduled for elective surgery. The primary outcome was mask ventilation difficulty assessed using the Warters scale.
Mask ventilation was significantly easier with remimazolam, with a median Warters score of 0.0 [0.0-0.8] versus 1.0 [0.0-3.0] for propofol (P=0.002). The odds of requiring more than one airway device were lower with remimazolam (OR 0.23, 95% CI 0.08-0.68, P=0.006). Mean blood pressure immediately after loss of consciousness was higher in the remimazolam group (P=0.037), though the incidence of hypotension after induction was comparable. Time to achieve loss of consciousness was significantly longer with remimazolam (P<0.001).
Adverse events, serious adverse events, discontinuations, and tolerability were not reported. The study has important limitations: it was a single trial with only 76 patients, and key safety details are absent. Funding and conflicts of interest were not reported. For practice, these findings suggest remimazolam may be associated with easier mask ventilation and better hemodynamic stability during induction compared to propofol in similar adult surgical populations, but the slower onset and limited evidence base require consideration.